News for BioXcel Therapeutics Stock (BTAI)

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 08/01/23

3 Stocks With Sky-High Short Interest Levels

MarketBeat • 07/31/23

BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023

GlobeNewsWire • 07/31/23

Kessler Topaz Meltzer & Check, LLP Notification: Deadline Reminder for BioXcel Therapeutics, Inc. (BTAI) Investors in Securities Class Action Lawsuit

PRNewsWire • 07/30/23

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

PRNewsWire • 07/28/23

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 07/28/23

BIOXCEL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire • 07/28/23

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire • 07/24/23

BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.

PRNewsWire • 07/24/23

BTAI Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against BioXcel Therapeutics, Inc. (BTAI) and Encourages Investors to Contact the Firm

PRNewsWire • 07/21/23

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

PRNewsWire • 07/20/23

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Business Wire • 07/19/23

INVESTOR DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $250,000 to Contact the Firm

Accesswire • 07/19/23

BioXcel Therapeutics, Inc. (BTAI) Class Action Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against BioXcel Therapeutics, Inc.

Business Wire • 07/18/23

BTAI INVESTOR DEADLINE: BioXcel Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

PRNewsWire • 07/15/23

Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

Business Wire • 07/13/23

ROSEN, A LEADING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

PRNewsWire • 07/13/23

3 Biotech Stocks to Sell Before They Damage Your Portfolio

InvestorPlace • 07/12/23

Attention BioXcel Therapeutics, Inc. (BTAI) Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against BioXcel Therapeutics, Inc.

PRNewsWire • 07/12/23

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

Business Wire • 07/11/23

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

Business Wire • 07/11/23

BTAI CLASS ACTION ANNOUNCEMENT:  Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against BioXcel Therapeutics, Inc. (BTAI)

Business Wire • 07/11/23

BIOXCEL SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI

Business Wire • 07/11/23

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against BioXcel Therapeutics, Inc. (BTAI)

Business Wire • 07/10/23

BTAI INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that BioXcel Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the BioXcel Class Action Lawsuit

Business Wire • 07/10/23